HR Execs on the Move


 
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aziyo.com
  • 12510 Prosperity Drive Suite 370
    Silver Spring, MD USA 20904
  • Phone: 240.247.1170

Executives

Name Title Contact Details
Ji Zhang
Director, Research and Development Profile
Darryl Roberts
Executive Vice President and General Manager, Musculoskeletal Products Profile

Similar Companies

Merck Millipore

Merck Millipore is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Creo

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.

Targeted Genetics Corporation

Targeted Genetics Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Emiliem Inc

Emiliem Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.